- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BOUNDLESS BIO Aktie jetzt für 0€ handeln | |||||
| 13.12.24 | Boundless Bio drops clinical-stage cancer drug over phase 1 data, shakes up C-suite | 2 | FierceBiotech | ||
| 12.12.24 | Boundless Bio, Inc.: Boundless Bio Announces Pipeline and Leadership Updates | 74 | GlobeNewswire (Europe) | Company elects not to advance BBI-825 into Part 2 portion of STARMAP clinical trial Third ecDTx program advancing, with plans for development candidate nomination by mid-2025 Operating runway extended... ► Artikel lesen | |
| 12.12.24 | Boundless Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.11.24 | Boundless Bio GAAP EPS of -$0.74 | 1 | Seeking Alpha | ||
| 07.11.24 | Boundless Bio, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.11.24 | Boundless Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 06.11.24 | Boundless Bio drug shrinks tumors in mice by targeting extrachromosomal DNA | 1 | FierceBiotech | ||
| 15.10.24 | Boundless Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.10.24 | Boundless Bio CFO Jami Rubin Steps Down For Personal Reasons | 1 | RTTNews | ||
| 14.10.24 | Boundless Bio CFO Jami Rubin tritt zurück | 2 | Investing.com Deutsch | ||
| 14.10.24 | Boundless Bio CFO Jami Rubin steps down | 1 | Investing.com | ||
| 14.10.24 | Boundless Bio CFO steps down | 1 | Seeking Alpha | ||
| 14.10.24 | Boundless Bio, Inc.: Boundless Bio Announces Departure of Chief Financial Officer | 179 | GlobeNewswire (Europe) | SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies... ► Artikel lesen | |
| 11.09.24 | Boundless Bio, Inc.: Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference | 2 | GlobeNewswire (USA) | ||
| 20.08.24 | Boundless Bio resets stock option prices to retain talent | 1 | Investing.com | ||
| 20.08.24 | Boundless Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.08.24 | Boundless Bio reports Q2 results | 1 | Seeking Alpha | ||
| 13.08.24 | Sluggish enrollment leads Boundless Bio to make 'modest' layoffs 5 months after $100M IPO | 1 | FierceBiotech | ||
| 13.08.24 | Boundless Bio, Inc. (BOLD): Why Should You Buy This New Penny Stock Now? | 4 | Insider Monkey | ||
| 13.08.24 | Boundless Bio streamlines operations, extends runway | 1 | Investing.com |
Seite:
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 112,80 | +0,18 % | Kaufempfehlung bekräftigt: BioNTech: Spannende Pipeline macht Hoffnung auf deutlichen Kursanstieg | © Foto: Julia Cebella - dpaDie Analysten von Berenberg Research sehen großes Potenzial in BioNTechs Onkologie-Pipeline und betonen, dass die bevorstehenden klinischen Auswertungen bis 2025 die Bewertung... ► Artikel lesen | |
| EVOTEC | 8,165 | +3,22 % | Evotec: Diese Supportzone darf nicht fallen | Die Befürchtung, dass der abrupte Abgang des langjährigen Vorstandschefs Langthaler vor gut einem Jahr problematisch würde, hat sich bestätigt. Evotec sortiert sich neu, das braucht Zeit und ist ergebnisoffen.... ► Artikel lesen | |
| CUREVAC | 3,660 | -0,49 % | CureVac Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| AMGEN | 264,20 | +0,65 % | Nepsis Inc. Boosts Position in Amgen Inc. (NASDAQ:AMGN) | ||
| NOVAVAX | 8,689 | -1,05 % | Novavax Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| BIOGEN | 138,70 | -0,43 % | Biogen Inc.: FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease | Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment
Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment... ► Artikel lesen | |
| ORGANOVO | 0,337 | +4,34 % | Organovo, Inc.: Organovo Announces Appointment of Norman Staskey as Chief Financial Officer | SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 2,160 | +3,85 % | Pre-market Movers: Loop Industries, Repare Therapeutics, Candel Therapeutics, Inovio Pharmaceuticals, iSpecimen | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.35 A.M. ET).In the Green Loop Industries, Inc. (LOOP) is up over 56% at $1.93.
iSpecimen... ► Artikel lesen | |
| MAINZ BIOMED | 5,695 | 0,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed initiiert klinische US-Studie zur Evaluierung der Leistungsfähigkeit des Tests der nächsten Generation zur Erkennung von fortgeschrittenen Adenomen in einer großen Patientenpopulation | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Studie
Mainz Biomed initiiert klinische US-Studie zur Evaluierung der Leistungsfähigkeit des Tests der nächsten Generation... ► Artikel lesen | |
| VIKING THERAPEUTICS | 33,130 | +0,73 % | Why Viking Therapeutics, Inc. (VKTX) Crashed Last Week | ||
| INTELLIA THERAPEUTICS | 10,735 | +2,63 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema | CAMBRIDGE, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| GENMAB | 201,90 | +0,30 % | Genmab A/S: Genmab Announces Net Sales of DARZALEX (daratumumab) for 2024 | Company Announcement Net sales of DARZALEX® in 2024 totaled USD 11,670 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,300 | +0,36 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Preliminary Full Year 2024 ORLADEYO (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y) | -ORLADEYO net revenue expected to be between $515-$535 million in 2025- -Total revenue (including RAPIVAB®) expected to be between $540-$560 million in 2025- -Company achieved operating profit in... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,360 | -1,73 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research): Buy / Kursziel: USD 8,50 | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH 22.11.2024 / 11:05 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG.... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,579 | -1,15 % | What Analysts Are Saying About Pacific Biosciences Stock |
Das Unternehmen BOUNDLESS BIO INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 2,400 Euro und damit -5,51 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BOUNDLESS BIO INC finden Sie auf Wallstreet Online.
